Implications of the 21st Century Cures Act
The Columbia University Bioethics Masters and Certificate programs are pleased to invite you to the third in our series of free, online webinars examining recent ethical and policy issues related to the pharmaceutical and device industries.
Please join us on April 20th at 6:30 pm ET for this online webinar, which will provide a forum for an informed examination of the 21st Century Cures Act. Dr. Robert Klitzman will moderate a discussion with a distinguished panel of experts. We will focus on the clauses of the Act that affect the drug development and FDA approval process, and the implications for different stakeholders, including patients, industry sponsors, healthcare providers, and payers.
This program is free and open to all.
For further information, please contact Lillian Ringel at ler2143 [[at]] columbia [[dot]] edu.
- Dr. Robert Klitzman, Director of the Masters in Bioethics Program
- Aaron Kesselheim, M.D., J.D., M.P.H., Associate Professor of Medicine at Harvard Medical School and Director, Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
- Kay Holcombe, M.S., Senior Vice President for Science Policy at the Biotechnology Innovation Organization (BIO)
- Eleanor (Ellie) Dehoney, M.S., Vice President of Policy and Advocacy, Research!America